Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab monotherapy for bone parameters in relapsed or refractory multiple myeloma
2017-003951-44Phase 2Completed
- Sponsor
- Hellenic Society of Hematology
- Start
- Nov 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of daratumumab in multiple myeloma (MM), sponsored by Hellenic Society of Hematology. Primary endpoint: Change from baseline in bone resorption markers CTX and TRACP-5b after 4 months of daratumumab monotherapy. Started Nov 2017; status: completed.
02
Drugs
daratumumab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2017-003951-44.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003951-44.